One Wealth Advisors LLC Takes Position in Novartis AG (NYSE:NVS)

Key Points

• One Wealth Advisors LLC has acquired 2,176 shares of Novartis AG, valued at approximately $244,000, as indicated in their latest Form 13F filing with the SEC.
• BNP Paribas has upgraded Novartis shares to a "strong-buy" rating, with analysts giving a consensus rating of "Hold" and an average price target of $123.67.
• Novartis reported a quarterly revenue of $14.05 billion, surpassing expectations, with a net margin of 25.64% and earnings per share (EPS) of $2.42.

One Wealth Advisors LLC purchased a new stake in Novartis AG (NYSE:NVS - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 2,176 shares of the company's stock, valued at approximately $244,000.

Several other large investors have also recently added to or reduced their stakes in the company. Nexus Investment Management ULC bought a new stake in shares of Novartis in the 1st quarter valued at approximately $25,000. Tsfg LLC grew its position in Novartis by 366.0% during the 1st quarter. Tsfg LLC now owns 233 shares of the company's stock worth $26,000 after acquiring an additional 183 shares during the last quarter. Raiffeisen Bank International AG bought a new stake in Novartis during the 4th quarter worth approximately $25,000. Alpine Bank Wealth Management bought a new stake in Novartis during the 1st quarter worth approximately $33,000. Finally, Park Square Financial Group LLC bought a new stake in Novartis during the 4th quarter worth approximately $30,000. Institutional investors and hedge funds own 13.12% of the company's stock.

Novartis Trading Down 0.9%

NVS traded down $1.06 during mid-day trading on Monday, reaching $116.65. The stock had a trading volume of 706,035 shares, compared to its average volume of 2,022,654. The stock has a market capitalization of $246.40 billion, a P/E ratio of 16.97, a P/E/G ratio of 1.66 and a beta of 0.59. The company has a debt-to-equity ratio of 0.53, a quick ratio of 0.62 and a current ratio of 0.82. The firm's fifty day simple moving average is $117.59 and its two-hundred day simple moving average is $111.24. Novartis AG has a 52 week low of $96.06 and a 52 week high of $124.83.

Novartis (NYSE:NVS - Get Free Report) last announced its quarterly earnings data on Thursday, July 17th. The company reported $2.42 EPS for the quarter, beating analysts' consensus estimates of $2.38 by $0.04. The firm had revenue of $14.05 billion for the quarter, compared to analyst estimates of $13.94 billion. Novartis had a return on equity of 41.08% and a net margin of 25.64%. The business's quarterly revenue was up 12.3% compared to the same quarter last year. During the same period last year, the company earned $1.97 EPS. On average, equities analysts predict that Novartis AG will post 8.45 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, BNP Paribas upgraded Novartis to a "strong-buy" rating in a research report on Tuesday, April 15th. Three analysts have rated the stock with a sell rating, six have given a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, Novartis currently has an average rating of "Hold" and an average target price of $123.67.

Novartis Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.